RCS - Ondine Biomedical - Leading Canadian Surgery Centre Adopts Steriwave

Ondine BiomedicalAnnouncement

30/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nRSd8599Oa&default-theme=true

RNS Number : 8599O  Ondine Biomedical Inc.  30 June 2025

30 June 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

 

 

Cambie Surgery Centre Adopts Steriwave(®) as Standard of Care for Orthopedic
and Plastic Surgeries

 

Ondine Biomedical Inc. (AIM: OBI) announces that its expansion is gaining
traction in Canada's private healthcare sector, with Cambie Surgery Centre,
one of the country's foremost private surgical facilities, adopting
Steriwave(®) nasal photodisinfection as the standard of care for orthopedic
and plastic surgeries. This is the third private clinic in Canada to routinely
use Steriwave before orthopedic and cosmetic surgery.

Established in 1996 as Canada's first free-standing private hospital, Cambie
Surgery Centre is one of Canada's leading private, multi-specialty surgical
centres, accredited with Exemplary Standing by Accreditation Canada. The
centre is renowned for its advanced technology, highly experienced surgeons,
and unwavering commitment to patient-focused care.

Cambie Surgery Centre's decision reflects a growing trend among Canadian
surgical facilities to embrace Steriwave nasal photodisinfection into their
infection prevention protocols. Steriwave's rapid, broad-spectrum action and
ease of use make it an ideal solution for busy surgical teams focused on
delivering the best outcomes for their patients.

Kirsty Carpenter, Executive Director of Cambie Surgery Centre in British
Columbia commented:

"At Cambie Surgery Centre, our mission is to provide the highest standard of
care for our patients. Adopting nasal photodisinfection aligns perfectly with
our commitment to best practices and patient safety. Antimicrobial resistance
is a real threat to our patients. We are proud to lead the way in British
Columbia by implementing this proven, innovative technology to ensure our
patients are maximally protected from the risk of infection."

Carolyn Cross, CEO of Ondine, commented:

"We are delighted to be working with Cambie Surgery Centre, an important
BC-based private surgery centre recognized for its excellence and leadership
in patient care.  By adopting Steriwave as standard of care for orthopedic
and plastic surgeries, Cambie Surgery Centre is taking a proactive step to
protect patients from the growing challenge of antibiotic resistance. We look
forward to supporting their team as they continue to set new benchmarks for
surgical safety in Canada."

Surgical site infections (SSIs) following major surgeries carry serious and
often devastating consequences for patients, with approximately 3% excess
mortality [ 1 ], extended hospital stays of nearly 10 days [ 2 ], and up to 63
hours of added staff time per case, based on internal modelling estimates. A
comprehensive Alberta study published in 2018 found that complex SSIs
following hip and knee surgeries cost hospitals up to CA$95,000 per case and
carry serious risks for patients.[ 3 ]

Approximately 69% of SSIs are caused by pathogens that colonize the nasal
passages.[ 4  5  (#_edn5) - 6 ] Leading health authorities, including the CDC
(Centers for Disease Control and Prevention), WHO (World Health Organisation),
and SHEA (Society for Healthcare Epidemiology of America), recommend nasal
decolonization prior to major surgeries to reduce SSI risk. Unlike topical
antibiotics such as mupirocin-commonly used for nasal decolonization but
limited by rising resistance and the need for multi-day patient
adherence-Steriwave eradicates a broader range of nasal pathogens linked to
SSIs, including drug-resistant strains.

Steriwave nasal photodisinfection has demonstrated more than a 50% reduction
in SSI rates in initial deployments, significantly improving patient outcomes
and reducing hospital readmissions. Steriwave is a five-minute,
light-activated antimicrobial therapy that destroys pathogens in the nasal
cavity without fostering resistance or relying on patient compliance. The
treatment involves applying the proprietary Steriwave photosensitive agent to
each nostril followed by illumination with a specific wavelength of red light.
Unlike antibiotics, it is immediately effective against bacteria, viruses, and
fungi, making it a powerful tool in the fight against healthcare-associated
infections.

 

Enquiries:

 Ondine Biomedical Inc.                                      www.ondinebio.com
 Carolyn Cross, CEO                                          +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                               +44 (0)20 7409 3494

 RBC Capital Markets (Broker)
 Kathryn Deegan                                              +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                            +44 (0)77 1000 5910

 

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada, Australia, Mexico and several other countries under the
name Steriwave(®). In the US, it has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

 

 

(#_ednref1) [ 1 ] Umscheid CA, et al. Estimating the proportion of
healthcare-associated infections that are reasonably preventable and the
related mortality and costs. Infection Control & Hospital Epidemiology,
2011;32(2):101-114. (link (https://doi.org/10.1086/657912) )

(#_ednref2) [ 2 ] Anderson DJ, et al. Strategies to Prevent Surgical Site
Infections in Acute Care Hospitals: 2014 Update. Infect. Control. Hosp.
Epidemiol. 2014;35:605-627. (link
(https://pmc.ncbi.nlm.nih.gov/articles/PMC4267723/) )

(#_ednref3) [ 3 ] Rennert-May ED, Conly J, Smith S, et al. The cost of
managing complex surgical site infections following primary hip and knee
arthroplasty: A population-based cohort study in Alberta, Canada. Infect
Control Hosp Epidemiol. 2018;39(10):1183-1188. (link
(https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/abs/cost-of-managing-complex-surgical-site-infections-following-primary-hip-and-knee-arthroplasty-a-populationbased-cohort-study-in-alberta-canada/D1039C9F16AC6FE965C960D6C2494201)
)

(#_ednref4) [ 4 ] CDC. HAI Pathogens and Antimicrob Resist Report, 2018-2021.
(link (https://www.cdc.gov/nhsn/hai-report/index.html) )

(#_ednref5) [ 5 ] Nature. 2012;486:207-214. (link
(https://www.nature.com/articles/nature11234) )

(#_ednref6) [ 6 ] Biomedicines. 2022 Dec 26;11(1):54. (link
(https://www.mdpi.com/2227-9059/11/1/54/review_report) )

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEKLFLEQLLBBE